Cardio-Oncology

Explore how to mitigate the effects of cancer on the heart.

Science News

Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship
Heart Disease and Stroke Statistics - 2024 Update
Cardiovascular Imaging in Contemporary Cardio-Oncology
Equity in Cardio-Oncology Care and Research
Heart Disease and Stroke Statistics - 2023 Update

Journals

Evolving Cardiac Safety in Drug Discovery: Time for Immunology Integration
Letter by Cardinale et al Regarding Article, “Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial”
Extracellular Vesicles: Bridging the Heart and Tumor in Reverse Cardio-Oncology
Response by Henriksen et al Regarding Article, “Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial”
Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta‐Analysis of Observational Studies and Randomized Controlled Trials
The CLCD Council supports AHA objectives in clinical cardiology, promotes excellent clinical care, and fosters professional development and education for clinical cardiologists. Through council-sponsored symposia, panels, and scientific conferences, members can access and interpret new developments in the field and promote clinical cardiology to professional and lay audiences.

The GPM Council seeks to advance discovery and translation of biological insights from genetics and omics technologies to improve cardiovascular and brain health through better risk prediction, treatment and prevention for patients. Our expertise spans genetics, genomics, genomic medicine, epigenetics, transcriptomics, metabolomics, proteomics, microbiome, bioinformatics, computational science, and population health.

CEO Nancy Brown on Cardio Oncology

CEO Nancy Brown explains why the AHA is funding a Strategically Focused Research Network on cardio-oncology with $15 million and, working with CancerLinQ LLC, making oncology datasets available on a version of the Precision Medicine Platform.

American Heart Association Professional Members

Enjoy instant benefits!

  • Free Online Access to AHA Scientific Journals
  • Affiliate with our 16 Scientific Councils
  • Discounts on Scientific Conference Registration and Online Courses

Learn more about Professional Membership